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Abstract: Toll-like receptors (TLRs) sense conserved structures of pathogens and influence macrophage functions. Here 
we investigated the impact of TLR signaling on the modulation of macrophage defense mechanisms against infection of 
Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis. We found that a synthetic derivative of the 
TLR2/6 agonist MALP-2 and the potent TLR4 agonist lipopolysaccharide inhibited the intracellular growth of MTB in 
murine macrophages. Likely the microbicidal effect was mediated by production of nitric oxide while it is still unclear  
the role played by release of TNF-, IL-6, MIP-1 and IL-10. These results suggest that the activation of microbicidal  
defense via TLR ligands is an appealing target for the establishment on immune intervention against tuberculosis.  
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INTRODUCTION 
  A series of pattern recognition receptors such as Toll-like 
receptors (TLRs) sense conserved structures of pathogens 
and activate dendritic cells (DC) and macrophages. Signals 
via TLRs enhance DC antigen-presentation and favour the 
development of B and T cell immunity during vaccination 
[1], thus several TLR ligands are under investigation as 
novel candidate vaccine adjuvant. On macrophages, trigger-
ing of TLRs promote the release of pro-inflammatory   
cytokines, chemokines, nitric oxide (NO), and prostagland-
ins [2, 3], which in turn can affect microbicidal defence 
mechanisms. The impact of TLR signalling on macrophage 
pathogen growth control is particularly relevant for those 
intracellular pathogens, such as Mycobacterium tuberculosis 
(MTB), which
  survive and grow primarily within host 
macrophages. MTB is the causative agent of tuberculosis 
(TB), a still dreadful infectious disease which causes of al-
most 2 million deaths per year [4]. MTB or its cell wall lip-
ids, bind to several TLRs expressed on macrophages. Myco-
bacterial ligands for TLR2 or the heterodimers TLR2/1 and 
TLR2/6 include the mycobacterial p19 lipoprotein arabinose-
capped Lipoarabinomannan (LAM), PIM, lipomannan and 
trehalose dimycolate; while for TLR9 the CpG-containing 
DNA, and for TLR4, a heat-sensitive but still unidentified 
mycobacterial component have been established as ligands 
[5, 6]. Engagement of macrophage TLRs by mycobacterial 
ligands promotes the expression of pro-inflammatory media-
tors (IL-12, IL-18, TNF-, MCP-1, and MIP1) and antimy-
cobacterial effectors (Irgm-1/LRG47, cathelicidin, NO and 
other reactive nitrogen intermediates), and also induces 
phagosome maturation [5, 7, 8, 9]. In addition, signalling   
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through MyD88, the adaptor molecule necessary for all TLR 
(apart from TLR3), is essential for protection against MTB 
infection in mice [10]. However, MTB has developed several 
immune-evasion mechanisms inside the macrophage, often 
through TLR ligands, such as the19 kDa mycobacterial   
lipoprotein, which dampen the innate immune response   
and allow MTB to survive also in activated macrophages 
[11-14].  
  In this variegate context, we asked whether non-
mycobacterial TLR ligands could modify intracellular MTB 
viability in infected macrophages. This should be addressed 
to verify whether TLR ligands could be new target for   
TB drugs and to evaluate the risk of TLR ligand-mediated 
adjuvant use in MTB-infected individuals. In the present 
study we investigated the effects resulting from TLR2/6   
engagement by a synthetic derivative of the Mycoplasma-
derived macrophage-activating lipopeptide of 2  kDa 
(MALP-2) and from TLR4 triggering by lipopolysaccharide 
(LPS) on murine MTB-infected macrophages. MALP-2   
derivatives are attractive candidate adjuvants for both   
mucosal and systemic vaccine formulations [15, 16]. In fact, 
MALP-2 derivatives induce secretion of pro-inflammatory 
cytokines/chemokines in DC [2, 17], enhance the capacity  
to process and present antigens to T and B cells [17],   
and increase memory adaptive immunity against co-
administered antigens [15, 16]. Among MALP-2 derivatives, 
the S-[2,3-bispalmitoyloxy-(2R)-propyl]-R-cysteinyl-amido-
monomethoxylpolyethyleneglyvcol, is a safe compound with 
low toxicity and pyrogenicity when administered in vivo 
[18]. The S-MALP-2 steroisomer is > 100 times less active 
than R-MALP-2 in stimulating the release of cytokines, 
chemokines and NO by macrophages [19]. Restricting TLR-
induced signals is very important since a strong, protracted 
and non controlled stimulation of TLRs can induce excessive 
inflammation, which could damage host tissues and even be 
lethal, as for example in case of septic shock induced by LPS 48    The Open Microbiology Journal, 2009, Volume 3  Palma et al. 
[18, 20]. Despite its high in vivo toxicity, LPS was used as a 
golden standard in our studies since it is one of the most  
potent inducer of macrophage activation in vitro. Moreover, 
LPS activates different pathways respect to those triggered 
by MTB TLR4 ligands [21] and activates NF-kB and   
IFN-responsive genes through MyD88-independent and -
dependent pathways in macrophages [22]. 
MATERIALS AND METHODS 
Microorganism  
  MTB H37Rv (ATCC 27294) was grown at 37°C in   
Middlebrook 7H9 medium under agitation (120 rpm) up to 
mid-exponential phase. Aliquoted stocks were stored at -
70°C until use; the titers of stocks were verified on a regular 
basis by counting the numbers of CFU on Middlebrook 
7H10 agar plates. 
Reagents 
 LPS  from  E. coli was purchased from Sigma Aldrich   
Co, St Louis, MO. The MALP-2 derivative of 3,000 Da,   
S-[2,3-bispalmitoyloxy-(2R)-propyl]-R-cysteinyl-amido 
monomethoxylpolyethyleneglyvcol, was synthesized and 
purified by silica gel chromatography (>95%), as previously 
described [15]. This derivative was free from LPS contami-
nation. 
Preparation of Murine Bone Marrow-Derived   
Macrophage  
  Bone marrow-derived macrophages  were prepared as 
previously described [23]. Briefly, bone marrow was flushed 
from femurs of healthy C57BL/6 mice with Dulbecco’s 
Modified Eagle’s Medium (DMEM) and cells were plated at 
2 x 10
6 in 24-well plates in complete DMEM medium 
(cDMEM: Fetal Bovine Serum 10%, L-glutamine 1%, -
mercapto-ethanol) with the addition of 10% L-929-
conditioned medium. After 1 day of incubation, the medium 
was replaced with antibiotic-free cDMEM supplemented 
with 10% L-929-conditioned medium. The cells were   
incubated for an additional 7 days, with medium replaced 
every 2 days before use in MTB-infection experiments. 
Infection of Macrophages with MTB 
  Following the 7-day culture period, the macrophage   
cultures were infected with MTB, according to the following 
protocol: bacteria were diluted from frozen stocks in 
cDMEM and added at a multiplicity of infection (MOI) of 
1:1 or 1:0.1 (macrophage to bacterium ratio) for 2 or 8 days 
of culture, respectively. MTB was co-incubated with macro-
phages at 37°C in 5% CO2 for 3 h and then washed 3 to 5 
times in DMEM to eliminate extracellular bacteria. Follow-
ing the last wash, cells were replaced in cDMEM and the 
stimuli (LPS and MALP-2) were added and left for the entire 
length of the experiments. Cells were infected with the two 
different MOI of infection in order to obtain after 2 or 8 days 
of culture a significant percentage of infected cells without 
evident sign of cell suffering (as checked by visualization  
of the macrophage culture by optical microscopy). After 2 or 
8 days of incubation culture fluids were filtered through 
membranes (pore size 0.22 μm, Millipore, Malsheim, 
France) and then used for cytokine/chemokine and nitrite 
detection. The bacterial load was evaluated through colony 
forming unit (CFU) assays after 8 days of macrophage   
culture. This time point was selected to allow that MTB-
triggered immune-evasion mechanisms, which reduce 
macrophage microbicidal power, could occur [14, 24]. 
CFU Assay 
  After 8 days of culture, the number of bacteria in macro-
phage culture was enumerated by CFU assay. Undiluted or 
diluted in distilled water culture supernatants were plated on 
Middlebrook 7H10 agar to evaluate the presence of external 
MTB. The intracellular MTB was revealed by lysing the 
macrophages with distilled water containing 0.1% saponin 
for 3 min, and then plating 10-fold dilutions in distilled   
water of the culture lysate on Middlebrook 7H10 agar. The 
MTB colonies were counted visually after 21 days of incuba-
tion. The value of CFU was the sum of both external and 
intracellular MTB CFU. In our macrophage cultures more 
than 96% of viable MTB were intramacrophagic, as calcu-
lated by enumerating MTB in supernatants and lysates. 
Cytokine Detection 
  MTB-infected macrophage culture supernatants were 
harvested at 2 and 8 days and assayed for IL-6, IL-10, MIP-
1-, MIP-1- and TNF- by specific quantitative sandwich 
ELISA Kits (mouse Quantikine, R&D System, Abingdon, 
UK), in accordance with the manufacture’s instructions. 
Quantification was made against a standard curve obtained 
for individual cytokine standards provided by manufacturer. 
Nitric Oxide Measurement 
  Culture supernatants were harvest at 48 h, and proteins 
were removed by ultrafiltration using 10,000 MW cut-off 
filters (Millipore). Nitric oxide concentrations were deter-
mined by colorimetric detection of nitrite as an azo dye 
product of the Griess Reaction using a specific colorimetric 
kit (Parameter
TM Total NO/nitrite/nitrate, R&D System). To 
measure total nitrite, an enzymatic conversion of nitrate to 
nitrite by nitrate reductase was performed, in accordance 
with the manufacturer’s instructions.  
Statistical Analysis 
  Statistical differences were determined by using ANOVA 
and Bonferroni’s multiple t-tests or Student’s t-test. Linear 
regression analysis was used to correlate amount of NO   
produced and MTB growth inhibition in macrophages 
treated with MALP-2 derivative or LPS. 
RESULTS AND DISCUSSION 
  The effect of the TLR2/6 agonist MALP-2 derivative, 
tested at concentrations ranging from 5-500 ng/ml on the 
intracellular growth of MTB in bone marrow-derived murine 
macrophages. An optimal concentration of LPS (500 ng/ml) 
was also tested in parallel to gain strong macrophage activa-
tion through TLR4. We found that macrophage treatment 
with the lowest concentrations of the MALP-2 derivative   
(5-50 ng/ml) and LPS significantly reduced the intracellular 
growth of MTB as compared to untreated MTB-infected 
macrophages (P<0.01 by ANOVA-Bonferroni’s multiple   
t-test or Student’s t-test) (Fig. 1  A and B). However, the   
degree of microbicidal effect induced by lower MALP-2 
derivative concentrations was significantly different from MALP-2 Inhibits M. tuberculosis Growth  The Open Microbiology Journal, 2009, Volume 3    49 
that conferred by LPS (P<0.05 LPS versus 50 ng/ml MALP-
2 derivative and P<0.01 LPS versus 5 ng/ml MALP-2   
derivative by ANOVA-Bonferroni’s multiple t-test). These 
data clearly demonstrated that the engagement of TLR2/6 
and TLR4 with non-mycobacterial ligands can activate mi-
crobicidal mechanisms in macrophages, suggesting that TLR 
deserve to be investigated as new targets for anti-TB drugs. 
In addition, considering that TLR2/6 and TLR4 are targets 
for many bacterial compounds, our finding suggests that the 
capability of macrophages to kill intracellular MTB may be 
modulated by the presence of co-infection or the presence of 
commensal microbial flora in MTB-infected individuals.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The MALP-2 derivative and LPS reduced intracellular replication of MTB in murine macrophages. Bone marrow-derived macro-
phages infected with MTB (MOI 1:0.1) were stimulated with either LPS or the MALP-2 derivative at the indicated concentrations. After 8 
days, bacteria in the macrophage cultures were enumerated by CFU assay, as described in Materials and Methods. In panel A, the number of 
CFU is shown as mean ± SEM of triplicate determinations of a single representative experiment out of 4. In panel B, the percentages of MTB 
growth are shown as the mean ± SEM of 4 independent experiments. Responses that were significantly different from control untreated 
macrophages are indicated by asterisks as revealed by both ANOVA-Bonferroni’s multiple t-test and Student’s t-test (*, P<0.05; ** P<0.01). 
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  Notably, the highest concentration of the MALP-2   
derivative (500 ng/ml) resulted in a poor control of MTB 
replication (Fig. 1 A, B). An ANOVA-Bonferroni’s multiple 
t-test revealed a significant difference (P<0.01) of MTB 
growth inhibition induced by lower MALP-2 derivative   
concentrations compared to the effect caused by the highest 
concentration. In the search of a mechanism to explain why 
lower concentrations of MALP-2 derivative were more   
effective in reducing MTB intracellular growth, we meas-
ured the release of NO, the most powerful anti-mycobacterial
 
defense mechanism in mice [25, 26]. In fact, a genetic dis-
ruption for the inducible NO synthase (iNOS) was associated 
with a significantly higher
 risk of dissemination and mortal-
ity in mice infected
  with MTB [27]. We found that the 
MALP-2 derivative, in a concentration dependent manner, 
and LPS, more potent, were NO inducers (Table 1). This 
suggests that the control mechanism
 for MTB intracellular
 
growth may rely heavily upon NO, although this does not 
rule out the possibility of other contributing mechanisms.
 
The microbicidal power of NO was however insufficient   
to induce MTB killing upon stimulation with the highest 
concentration of the MALP-2 derivative. In fact, despite   
a consistent NO production, no MTB load reduction was 
observed. In addition, the relatively weak NO induction   
observed after treatment with the lowest concentrations   
of MALP-2 derivative was sufficient to achieve intra-
macrophagic killing of MTB, in comparison with the   
high level of NO induction observed after LPS treatment. 
Thus, a linear regression analysis revealed no correlation 
(R=0.2) between amount of NO produced and inhibition of 
MTB growth in macrophages treated with LPS or MALP-2 
derivative. These data indicate that after reaching a critical 
threshold higher concentrations of MALP-2 derivative or 
LPS have no additional effect, rather they can even antago-
nize the NO-mediated killing of MTB. This is not   
completely surprising in view of the capacity of MTB to 
adapt to the NO synthesized by activated macrophages by 
either deploying NO scavengers or excluding iNOS from the 
phagosomes [28].  
  On the other hand, the release of other mediators by   
activated macrophages may contribute to MTB survival   
independently from a direct effect on the NO pathways. 
Thus, we investigated macrophage production of IL-6, IL-
10, TNF- and MIP-1. TNF- is a cytokine critically
 im-
portant for host defense against MTB infection [29], which 
enhances release of reactive nitrogen intermediates from 
macrophages [30, 31]. However, the production of this cyto-
kine does not always correlate with the extent of growth con-
trol in MTB-infected macrophages [32, 33]. Infection with 
virulent MTB strains induced the secretion of higher levels 
of bioactive TNF- than attenuated strains, which in turn 
correlates with their ability to multiply intracellularly. 
Treatment of human infected macrophages with anti-TNF- 
antibodies reduces the growth rate of intracellular bacteria, 
whereas bacterial replication is augmented by addition   
of exogenous TNF- [34]. On the other hand, MIP-1  
was found to suppress intracellular MTB growth and its 
diminution may promote intracellular survival of MTB   
in human macrophages [35]. IL-6, a cytokine required for 
protection against MTB infection [36], can reduce the activa-
tion of uninfected macrophages, thereby contributing to   
the inability of the immune response to eradicate infection 
[37]. Finally, IL-10, an important negative regulator of Th1 
immunity in tuberculosis [38], can also inhibit macrophage 
activation [39]. With this background, we measured the pro-
duction of the above cytokine by MTB-infected cells, treated 
or untreated with the MALP-2 derivative or LPS. We found 
that after 2 days of culture, LPS greatly induced production 
of IL-6, MIP-1 and TNF- in MTB-infected macrophages 
(Table 1). Although to a lesser extent than that observed for 
LPS, the highest concentrations of the MALP-2 derivative 
enhanced release of these three cytokines, whereas only IL-6 
secretion was enhanced at low MALP-2 derivative concen-
trations (Table 1). After 8 days of culture, we observed that 
upon LPS stimulation, the accumulation of both IL-6   
and TNF- was still greater compared to untreated MTB-
infected macrophages, whereas MIP-1 accumulation   
was reduced (Table 1). Similar results, with the exception  
of almost undetectable TNF- secretion, were obtained at 
the highest concentrations of the MALP-2 derivative, 
whereas the lower concentrations of MALP-2 reduced only, 
in a concentration dependent manner, the accumulation of 
MIP-1. The accumulation of IL-10, after 2 or 8 days of 
culture, was modified neither by LPS nor by the MALP-2 
derivative. 
  Although the secretion of these mediators does not allow 
a clear elucidation of their correlation with MTB viability, 
we observed that, the enhancement of MTB intra-
macrophagic killing by the MALP-2 derivative is unrelated 
to the production of these selected cytokines. In fact, the 
MALP-2 derivative killed intracellular MTB without the 
need to secrete TNF- and by inducing only very weak IL-6 
secretion. This is an important advantage in the context of 
potential in vivo application, since TNF- is the main re-
sponsible for LPS-mediated lethal toxicity [20] and IL-6 is a 
potent pyrogenic mediator [40]. Moreover, we can speculate 
that the enhancement of IL-6 and TNF- secretion observed 
in MTB-infected macrophages upon stimulation with either 
LPS or the highest concentration of MALP-2 may have   
promoted mechanisms favoring MTB replication at the   
expense of NO-mediated killing.  
  In conclusion, the MALP-2 derivative, at low concentra-
tions, reduces intracellular growth of MTB without the need 
of releasing pro-inflammatory mediators implicated in sys-
temic toxicity. Our data also suggest that it can be proposed 
the safe use of the MALP-2 derivative as adjuvant in MTB-
infected people, since it has not increased MTB replication, 
even at the highest concentrations tested. The opportunity to 
modulate macrophage anti-mycobacterial defense mecha-
nisms through low toxic non-mycobacterial TLR ligands 
opens favorable perspectives towards the development of 
new anti-MTB drugs, which are urgently needed for this 
dreadful disease.  
ACKNOWLEDGEMENTS 
  This study was supported in part by the grant H51 from 
the Ministero della Salute (Italy) and the grant LSHP-CT-
2003-503240 (MUVAPRED Project, European Community). 
  We are grateful to Giovanni Piccaro and Antonio Di   
Virgilio for mouse housing and technical assistance.  MALP-2 Inhibits M. tuberculosis Growth  The Open Microbiology Journal, 2009, Volume 3    51 
REFERENCES 
[1]    Benko S, Megyarics Z, Szabo A, Rajnevolgyi E. Dendritic cell 
subtypes as primary targets of vaccines: the emerging role and 
cross-talk of pattern recognition receptors. Biol Chem 2008; 389: 
469-85. 
[2]    Takeuchi O, Kawai T, Muhlradt PF, et al. Discrimination of   
bacterial lipoproteins by toll-like receptor 6. Int Immunol 2001; 13: 
933-40. 
[3]   Kaufmann A, Muhlradt PF, Gemsa D, Sprenger H. Induction of 
cytokines and chemokines in human monocytes by Mycoplasma 
Fermentans-derived lipoprotein MALP-2. Infect Immun 1999; 67: 
6303-8. 
[4]    World Health Organization (WHO). Global tuberculosis control: 
surveillance, planning, financing. Geneva, WHO, 2006. (WHO/ 
HTM/TB/2006.362) 
[5]   Quesniaux V, Fremond C, Jacobs M, et al. Toll-like receptor path-
ways in the immune responses to mycobacteria. Microbes Infect 
2004; 6: 946-59. 
[6]   Zahringer U, Lindner B, Inamura S, Heine H, Alexander C. TLR2-
promiscuous or specific? A critical re-evaluation of a receptor   
expressing apparent broad specificity. Immunobiology 2008; 213: 
205-24. 
[7]    Ryffel B, Fremond C, Jacobs M, et al. Innate immunity to   
mycobacterial infection in mice: critical role for toll-like receptors. 
Tuberculosis (Edinb.) 2005; 85: 395-405.  
[8]   Means TK, Wang S, Lien E, Yoshimura A, Golenbock DT, Fenton 
MJ. Human toll-like receptors mediate cellular activation by   
Mycobacterium tuberculosis. J Immunol 1999; 163: 3920-7. 
[9]   Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a 
vitamin D-mediated human antimicrobial response. Science 2006; 
311: 1770-3. 
[10]   Scanga CA, Bafica A, Feng CG, Cheever AW, Hieny S, Sher A. 
MyD88-deficient mice display a profound loss in resistance to   
Mycobacterium tuberculosis associated with partially impaired Th1 
cytokine and nitric oxide synthase 2 expression. Infect Immun 
2004; 72: 2400-4. 
[11]   Pai RK, Pennini ME, Tobian AA, Canaday DH, Boom WH,   
Harding CV. Prolonged toll-like receptor signaling by Mycobacte-
rium tuberculosis and its 19-kilodalton lipoprotein inhibits gamma 
interferon-induced regulation of selected genes in macrophages.   
Infect Immun 2004; 72: 6603-14. 
[12]   Fulton SA, Reba SM, Pai RK, et al. Inhibition of major histocom-
patibility complex II expression and antigen processing in murine 
alveolar macrophages by Mycobacterium bovis BCG and the   
19-kilodalton mycobacterial lipoprotein. Infect Immun 2004; 72: 
2101-10. 
[13]   Vazquez N, Greenwell-Wild T, Rekka S, Orewstein JM, Wahl SM. 
Mycobacterium avium-induced SOCS contributes to resistance   
to IFN-gamma-mediated mycobactericidal activity in human   
macrophages. J Leukoc Biol 2006; 80: 1136-44. 
[14]   Noss EH, Pai RK, Sellati TJ, et al. Toll-like receptor 2-dependent 
inhibition of macrophage class II MHC expression and antigen 
processing by 19-kDa lipoprotein of Mycobacterium tuberculosis. J 
Immunol 2001; 167: 910-8. 
[15]    Rharbaoui F, Drabner B, Borsutzky S, et al. The mycoplasma-
derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur J 
Immunol 2002; 32: 2857-65. 
[16]   Rharbaoui F, Westendorf A, Link C, et al. The Mycoplama-derived 
macrophage-activating 2-Kda lipopetide triggers global immune 
activation on nasal mucosa-associated lymphoid tissues. Infect 
Immun 2004; 72: 6978-86. 
[17]   Link C, Gavioli R, Ebensen T, Canella A, Reinhard E, Guzman 
CA. The toll-like receptor ligand MALP-2 stimulates dendritic cell 
maturation and modulate proteasome composition and activity. Eur 
J Immunol 2004; 34: 899-907. 
 [18]   Dieters U, Gumenscheimer M, Galanos C, Muhlradt PF. Toll-like 
receptor 2- and 6-mediated stimulation by macrophage-activating 
lipopeptide 2 induces lipopolysaccharide (LPS) cross tolerance in 
mice, which results in protection from tumor necrosis factor alpha 
but in only partial protection from lethal LPS doses. Infect Immun 
2003; 71: 4456-62. 
[19]   Takeuchi O, Kaufmann A, Grote K, et al. Cuttinge edge: preferen-
tially the R-stereoisomer of the mycoplasmal lipopeptide macro-
phage-activating lipopeptide-2 activates immune cells through a 
toll-like receptor 2- and MyD88-dependent signaling pathway. J 
Immunol 2000; 164: 554-7. 
[20]   Freudenberg MA, Galanos C. Tumor necrosis factor alpha mediates 
lethal activity of killed gram negative and gram-positive bacteria  
in D-galactosamine-treated mice. Infect Immun 1991; 59: 2110-5. 
[21]   Means TK, Jones BW, Schromm AB, et al. Differential effects of a 
Toll-like receptor antagonist on Mycobacterium-tuberculosis-
induced macrophage responses. J Immunol 2001; 166: 4074-82. 
[22]   Toshchakov V, Jones BW, Perera P-Y, et al. TLR4, but not TLR2, 
mediates IFN--induced STAT1/-dependent gene expression in 
macrophages. Nat Immunol 2002; 3: 392-8. 
Table 1.  Cytokine, Chemokine and Nitrite in the Culture Supernatant Fluids of Murine MTB-Infected Bone-Marrow-Derived 
Macrophages Stimulated with the MALP-2 Derivative or LPS 
Stimuli   Days  MOI  TNF- IL-6  IL-10  MIP-1 NO2 
     pg/ml pg/ml pg/ml pg/ml  μMol/L 
Untreated 2  1:1  0  188±62  92±2  1068±38  4.34±0.9 
 8  1:0.1  0 207±52  304±69  8078±148  n.d. 
MALP-2 2  1:1  25±10  824±23
* 129±10 970±40  13.05±0.75
* 
 5 ng/ml  8  1:0.1  0  211±53  260±15  7000±75
* n.d. 
MALP-2 2  1:1  20±5  1243±7
* 102±6 1112±25  19.25±0.35
** 
50 ng/ml  8  1:0.1  0  301±44  418±90  6587±70
* n.d. 
MALP-2 2  1:1  70±6
* 1470±64
* 126±6 1537+19
* 50.65±0.95
** 
500 ng/ml  8  1:0.1  10±5  538±151
* 361±89  5821±115
* n.d 
 LPS  2  1:1  1879±39
**,## 2138±88
**,# 109±12  6846±225
**,##  142.4±1.8
**,## 
500 ng/ml  8  1:0.1  336±52
**,## 1284±69
**,# 504±91 6709±217
*  n.d. 
a)Murine macrophages were infected with MTB at MOI 1:1 for 2 days or at MOI 1:0.1 for 8 days and cultured in the presence of LPS or the MALP-2 derivative at the indicated 
concentration. Culture supernatants harvested at the indicated time points were used for IL-6, IL-10, TNF-, MIP-1 detection by specific quantitative sandwich ELISA Kits. The 
results are presented as mean.  
± SEM in pg/ml. Pooled data of 3 independent experiments are shown. Nitrite was detected at 2 days with a specific colorimetric kit. The results are presented as mean ± SEM in 
μMol/L. Pooled data of 3 independent experiments are shown. 
*p<0.05 and 
**p<0.01, level of statistical significance between cytokine or nitrite release in stimulated versus untreated macrophages.  
#p<0.05 and 
##p<0.01, level of statistical significance between cytokine or nitrite release in LPS-treated versus MALP-2 derivative-stimulated macrophages. 52    The Open Microbiology Journal, 2009, Volume 3  Palma et al. 
[23]   Cowley SC, Elkins KL. CD4
+ T cells mediate IFN--independent 
control of Mycobacterium tuberculosis infection both in vitro and 
in vivo. J Immunol 2003; 171: 4689-99. 
[24]    Ting LM, Kim AC, Cattamanchi A, Ernst JD. Mycobacterium 
tuberculosis inhibits IFN-gamma transcriptional responses without 
inhibiting activation of STAT1. J Immunol 1999; 163: 3898-906. 
[25]    Chan J, Xing Y, Magliozzo RS, Bloom BR. Killing of virulent 
Mycobacterium tuberculosis by reactive nitrogen intermediates 
produced by activated murine macrophages J Exp Med 1992; 175: 
1111-22. 
[26]   Chan ED, Chan J, Schluger NW. What is the role of nitric oxide in 
murine and human host defense against tuberculosis? Current 
knowledge. Am J Respir Cell Mol Biol 2001; 25: 606-12.  
[27]    MacMicking JD, North RJ, La Corse R, Mudgett JS, Shah SK, 
Nathan CF. Identification of nitric oxide synthase as a protective 
locus against tuberculosis. Proc Natl Acad Sci USA 1997; 94: 
5243-8. 
[28]   Davis AS, Vergne I, Master SS, Kyei GB, Chua J, Deretic V. 
Mechanism of inducible nitric oxide synthase exclusion from 
mycobacterial phagosomes. PLoS Pathog 2007; 3: e186. 
[29]    Roach DR, Bean AG, Demangel C, France MP, Briscoe H,   
Britton WJ. TNF regulates chemokine induction essential for cell 
recruitment, granuloma formation, and clearance of mycobacterial 
infection. J Immunol 2002; 168: 4620-7. 
[30]   Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-
alpha is required in the protective immune response against   
Mycobacterium tuberculosis in mice. Immunity 1995; 2: 561-72.  
[31]   Bean AG, Roach DR, Briscoe H, et al. Structural deficiencies in 
granuloma formation in TNF gene-targeted mice underlie the 
heightened susceptibility to aereosol Mycobacterium tuberculosis 
infection, which is not compensated for by lymphoyoxin. J   
Immunol 1999; 162: 3504-11. 
[32]   Freeman S, Post FA, Bekker LG, et al. Mycobacterium tuberculo-
sis H37Ra and H37Rv differential growth and cytokine/chemokine 
induction in murine macrophages in vitro. J Interferon Cytokine 
Res 2006; 26: 27-33. 
[33]    Byrd TF. Tumor necrosis factor alpha (TNF alpha) promotes 
growth of virulent Mycobacterium tuberculosis in human mono-
cytes iron-mediated growth suppression is correlated with   
decreased release of TNF alpha from iron-treated infected   
monocytes. J Clin Invest 1997; 99: 2518-29.  
[34]    Engele M, Stossel E, Castiglione K, et al. Induction of TNF   
in human alveolar macrophages as a potential evasion mechanism 
of virulent Mycobacterium tuberculosis. J Immunol 2002; 
168:1328-37. 
[35]    Saukkonen JJ, Bazydlo B, Thomas M, Strieter RM, Keane J,   
Kornfeld H. B-chemokines are induced by Mycobacterium tubercu-
losis and inhibit its growth. Infect Immun 2002; 70: 1684-93. 
[36]   Ladel CH, Blum C, Dreher A, Reifenberg K, Kopf M, Kaufmann 
SH. Lethal tuberculosis in interleukin-6-deficient mutant mice.   
Infect Immun 1997; 65: 4843-9. 
[37]    Leal IS, Flórido M, Andersen P, Appelberg R. Interleukin-6   
regulates the phenotype of the immune response to a tuberculosis 
subunit vaccine. Immunology 2001; 103: 375-81. 
[38]   Boussiotis VA, Tsai EY, Yunis EJ, et al. IL-10-producing T cells 
suppress immune responses in anergic tuberculosis patients. J Clin 
Invest 2000; 105: 1317-25. 
[39]    Lang R, Rutschman RL, Greaves DR, Murray PJ. Autocrine   
deactivation of macrophages in transgenic mice constitutively 
overexpressing IL-10 under control of the human CD86 promoter. J 
Immunol 2002; 168: 3402-11. 
[40]    Dinarello CA. Cytokines as endogenous pyrogens. J Infect Dis 
1999; 179: S294-304.  
 
 
Received: March 10, 2009  Revised: March 17, 2009  Accepted: March 18, 2009 
 
© Palma et al.; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-
nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. 
 